Evidence map›Paper›PMID 42445303›Full record

ReviewPeerJ2026

Liposomes in drugs, nutraceuticals, and cosmetics.

Eleaneth Baltodano Viales, Gustavo Alonso Carazo Berrocal, Jorge Andrés Pacheco Molina, Fredy Barrantes Pérez, German Leonardo Madrigal Redondo

Abstract readReview
In one paragraph

Review in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Eleaneth Baltodano VialesInstituto de Investigaciones Farmacéuticas (INIFAR), Facultad de Farmacia, University of Costa Rica, Montes de Oca, San José, Costa Rica.
Gustavo Alonso Carazo BerrocalInstituto de Investigaciones Farmacéuticas (INIFAR), Facultad de Farmacia, University of Costa Rica, Montes de Oca, San José, Costa Rica.
Jorge Andrés Pacheco MolinaInstituto de Investigaciones Farmacéuticas (INIFAR), Facultad de Farmacia, University of Costa Rica, Montes de Oca, San José, Costa Rica.
Fredy Barrantes PérezInstituto de Investigaciones Farmacéuticas (INIFAR), Facultad de Farmacia, University of Costa Rica, Montes de Oca, San José, Costa Rica.
German Leonardo Madrigal RedondoInstituto de Investigaciones Farmacéuticas (INIFAR), Facultad de Farmacia, University of Costa Rica, Montes de Oca, San José, Costa Rica.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Liposomes are spherical vesicular structures formed by lipid bilayers with a hydrophilic internal nucleus. The size varies from about 20 nanometers to several micrometers. They were initially described in the sixties by the biophysicist Alec Bangham. Since then, multiple studies have been conducted to characterize them according to the number of layers: unilamellar, bilayers, multilamellar vesicles, and vesicles containing more vesicles called multivesicular vesosomes; size: between 0.025 µm and 2.5 µm, and functionality: Drug delivery system, cosmetic, nutraceutics. Moreover, there are several conventional and new methods for liposome preparation. For conventional liposomes, multiple technologies have been developed to enhance or impart specific characteristics, depending on the intended application of the liposomes, such as long-circulation liposomes, cationic liposomes, immunoliposomes, and specific stimulus-sensitive liposomes. In the medical field, liposomes are used in many routes of administration. Parenteral routes include most approved liposomal drugs; oral drugs have benefited from improved bioavailability. Pulmonary routes have emerged as an alternative to increase residence time and, therefore, therapeutic efficacy. Ocular routes are widely studied because liposomes are biodegradable and biocompatible. Nutraceuticals have emerged as an alternative or complementary therapy to treat many diseases, and liposomes enhance the bioavailability of these molecules. Liposomes also benefit the cosmetic industry by encapsulating substances, enhancing permeability, and enabling controlled release. Methodology: A bibliographic review was carried out by consulting databases such as ScienceDirect, PubMed, Wiley Online Library, Multidisciplinary Digital Publishing Institute (MDPI), National Center for Biotechnology Information (NCBI), Directory of Open Access Journals (DOAJ), and Nature. The keywords used were liposomes, liposomes and cosmetics, liposomes and cosmeceuticals, liposomes and nanotechnology, Transferosomes Results and Conclusion: These vesicles have a particular scientific relevance in the pharmaceutical, nutraceutical, and cosmetic fields. They are promising vehicles or carriers for substances and compounds that are unstable under specific conditions and can be easily degraded or have undesirable taste and smell. However, despite their advantages, challenges remain, including low solubility, limited half-life, oxidation, and hydrolysis of the phospholipids that form their membranes, and elevated production costs.

Indexed as

CosmeticsDietary SupplementsDrug Delivery SystemsLiposomesHumansPharmaceutical PreparationsCosmeticsLiposomesPharmaceutical PreparationsBioavailabilityCosmeticsDrugsLipidic bilayersLiposomesNutraceuticalsPhospholipid membranes

Identifiers

PMID42445303
PMCPMC13360747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.